1.15
-0.05 (-4.17%)
| Penutupan Terdahulu | 1.20 |
| Jumlah Dagangan | 59,368 |
| Harga / Jualan (P/S) | 2.60 |
| Harga / Buku (P/B) | 1.59 |
| Julat 52 Minggu |
| Margin Keuntungan | -224.45% |
| Margin Operasi (TTM) | -1,190.34% |
| EPS Cair (TTM) | -1.32 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -71.90% |
| Nisbah Semasa (MRQ) | 6.79 |
| Aliran Tunai Operasi (OCF TTM) | -12.57 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -7.74 M |
| Pulangan Atas Aset (ROA TTM) | -51.17% |
| Pulangan Atas Ekuiti (ROE TTM) | -97.29% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Marker Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -2.33 |
|
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.42% |
| % Dimiliki oleh Institusi | 36.13% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Concurrent Investment Advisors, Llc | 30 Jun 2026 | 67,963 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |